Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: psychedelic-based therapeutics - Clearmind Medicine/SciSparc

Drug Profile

Research programme: psychedelic-based therapeutics - Clearmind Medicine/SciSparc

Latest Information Update: 29 Feb 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Clearmind Medicine; SciSparc
  • Developer Clearmind Medicine; Hebrew University of Jerusalem; SciSparc
  • Class Antipsychotics; Behavioural disorder therapies; Neuropsychotherapeutics; Obesity therapies
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Metabolic disorders; Obesity; Psychiatric disorders

Most Recent Events

  • 27 Feb 2024 Clearmind Medicine has seven patent pending for various combinations with 5-methoxy-2-aminoindane in the multiple countries worldwide
  • 27 Feb 2024 SciSparc and Clearmind Medicine has patents pending for compositions of 3,4-methylenedioxymethamphetamine (MDMA), ibogaine, and ketamine, each combined with palmitoylethanolamide (“PEA”) in the US
  • 20 Feb 2024 Clearmind Medicines files three patent applications USPTO for combinations of 3, 4-methylenedioxymethamphetamine (MDMA), ibogaine and ketamine, MEAI compound (5-methoxy-2-aminoindane), lysergic acid diethylamide, psilocybin, and N,N-dimethyltryptamine each with palmitoylethanolamide (PEA), in the US under the international Patent Cooperation Treaty
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top